Goldman Sachs’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-279,225
| Closed | -$3.13M | – | 6940 |
|
|
2017
Q3 | $3.13M | Sell |
279,225
-51,430
| -16% | -$567K | ﹤0.01% | 3583 |
|
|
2017
Q2 | $3.64M | Buy |
330,655
+103,534
| +46% | +$1.04M | ﹤0.01% | 3325 |
|
|
2017
Q1 | $2.23M | Sell |
227,121
-117,993
| -34% | -$1.18M | ﹤0.01% | 3643 |
|
|
2016
Q4 | $3.73M | Buy |
345,114
+22,372
| +7% | +$224K | ﹤0.01% | 3310 |
|
|
2016
Q3 | $3.31M | Buy |
322,742
+25,953
| +9% | +$283K | ﹤0.01% | 3396 |
|
|
2016
Q2 | $3.88M | Sell |
296,789
-103,132
| -26% | -$1.35M | ﹤0.01% | 3074 |
|
|
2016
Q1 | $4.4M | Buy |
399,921
+120,916
| +43% | +$1.08M | ﹤0.01% | 2822 |
|
|
2015
Q4 | $2.57M | Buy |
279,005
+88,647
| +47% | +$742K | ﹤0.01% | 3420 |
|
|
2015
Q3 | $1.32M | Sell |
190,358
-3,364
| -2% | -$28.8K | ﹤0.01% | 4195 |
|
|
2015
Q2 | $1.9M | Buy |
193,722
+19,371
| +11% | +$176K | ﹤0.01% | 3870 |
|
|
2015
Q1 | $1.54M | Sell |
174,351
-2,108
| -1% | -$16.8K | ﹤0.01% | 4028 |
|
|
2014
Q4 | $1.55M | Buy |
176,459
+93,831
| +114% | +$760K | ﹤0.01% | 4117 |
|
|
2014
Q3 | $569K | Buy |
82,628
+9,317
| +13% | +$55.8K | ﹤0.01% | 5145 |
|
|
2014
Q2 | $385K | Buy |
73,311
+464
| +0.6% | +$2.26K | ﹤0.01% | 5558 |
|
|
2014
Q1 | $331K | Sell |
72,847
-11,419
| -14% | -$55.2K | ﹤0.01% | 5655 |
|
|
2013
Q4 | $425K | Buy |
84,266
+10,746
| +15% | +$51.7K | ﹤0.01% | 5420 |
|
|
2013
Q3 | $372K | Sell |
73,520
-15,955
| -18% | -$88.8K | ﹤0.01% | 5403 |
|
|
2013
Q2 | $443K | Buy |
+89,475
| New | +$426K | ﹤0.01% | 5042 |
|
Goldman Sachs's SCLN Position: Q4 2017 in Review
Goldman Sachs sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 279,225 shares — an estimated $3.13M sold.
Goldman Sachs first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $4.4M in Q1 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Goldman Sachs reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Goldman Sachs sold 279,225 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $3.13M.
- Goldman Sachs first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Goldman Sachs's Sciclone Pharmaceuticals Inc position peaked at $4.4M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Goldman Sachs's 13F filing for Q4 2017, filed 14 Feb 2018.